Streetbeat News

Price Targets

ATNM

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Actinium Pharma (AMEX:ATNM) but lowers the price target from $53 to $50.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:48 am

INTR

HSBC analyst Neha Agarwala maintains a Buy rating on Inter & Co (NASDAQ:INTR) and raises the price target from $4.5 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:47 am

BIOR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $65 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:47 am

ICCM

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) and maintained a price target of $3.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:46 am

APP

Truist Securities analyst Matthew Thornton has maintained a 'Buy' rating on AppLovin (NASDAQ:APP) and raised the price target from $35 to $45.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:46 am

CLSD

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:45 am

MGNI

Truist Securities analyst Matthew Thornton has maintained a 'Buy' rating on Magnite (NASDAQ:MGNI) but lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:45 am

SHPW

Needham analyst James Ricchiuti has maintained a 'Buy' rating on Shapeways Holdings (NASDAQ:SHPW) but lowered the price target from $8 to $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:45 am

ACLX

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Arcellx (NASDAQ:ACLX) and raises the price target from $49 to $50.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:43 am

ALPN

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $11 to $17.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:41 am